SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Gland Pharma - Quaterly Results

04 Nov 2025 Evaluate
The total revenue for the quarter ended September 2025 remained nearly unchanged at Rs. 10741.52 millions.A slim rise of 7.20% was recorded in the Net profit for the quarter ended September 2025 to Rs. 3019.95  millions  From Rs. 2817.10 millions.Operating profit surged to 4574.79 millions from the corresponding previous quarter of 4216.03 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202509 202409 % Var 202509 202409 % Var 202503 202403 % Var
Sales 10741.52 10629.90 1.05 21129.87 20750.14 1.83 41161.49 41674.28 -1.23
Other Income 825.92 578.03 42.89 1373.33 1062.93 29.20 2150.75 1666.66 29.05
PBIDT 4574.79 4216.03 8.51 8710.65 7636.46 14.07 16576.93 15754.47 5.22
Interest 39.71 1.72 2208.72 114.06 10.83 953.19 228.37 78.43 191.18
PBDT 4535.08 4214.31 7.61 8596.59 7625.63 12.73 16348.56 15676.04 4.29
Depreciation 448.35 416.15 7.74 886.03 824.32 7.49 1692.71 1621.07 4.42
PBT 4086.73 3798.16 7.60 7710.56 6801.31 13.37 14655.85 14054.97 4.28
TAX 1066.78 981.06 8.74 1998.03 1755.00 13.85 3758.32 3621.72 3.77
Deferred Tax 7.80 17.74 -56.03 6.34 29.56 -78.55 91.24 246.84 -63.04
PAT 3019.95 2817.10 7.20 5712.53 5046.31 13.20 10897.53 10433.25 4.45
Equity 164.76 164.75 0.01 164.76 164.75 0.01 164.76 164.71 0.03
PBIDTM(%) 42.59 39.66 7.38 41.22 36.80 12.02 40.27 37.80 6.53

Gland Pharma Share Price

1795.80 59.80 (3.44%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×